T1	Participants 603 725	Patients who met remission criteria at 2 consecutive weekly visits during 6 to 12 weeks of open-label olanzapine treatment
T2	Participants 210 335	patients with manic and mixed mood episodes, olanzapine has proven effective in maintaining response, as compared to placebo.
T3	Participants 159 177	bipolar 1 disorder
